Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212486 | 1.00 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL9389379 | 1.00 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL3260894 | 0.94 | ACE (0.45) | ACEREN | |
| SCHEMBL17234222 | 0.88 | ACE (0.37) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL7827074 | 0.88 | ACE (0.37) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL17234226 | 0.88 | ACE (0.37) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL28128812 | 0.86 | DPP4 (0.40) | ACE | |
| Hydrochloric Acid SCHEMBL28488246 | 0.84 | SPHK1 (0.39) | — | |
| SCHEMBL163319 | 0.83 | LMNA (0.54) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL30305374 | 0.83 | LMNA (0.54) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-0965327-B1 | WRINKLING MODIFIERS | KAO CORP (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6436920-B1 | AN ANTIWRINKLE AND ANTIAGING AGENT (COSMETIC SKIN CARE AGENT) COMPRISING A GUANIDINE DERIVATIVE | KAO CORPORATION (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020022611-A1 | Wrinkling modifiers | KAO CORPORATION (JP) | 2002-02-21 | — | — | US | disclosed |
| US-6306848-B1 | SKIN TREATMENT | KAO CORPORATION (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0965327-A1 | WRINKLING MODIFIERS | Kao Corporation (JP) | 1999-12-22 | — | — | EP | disclosed |
| US-3972872-A | BACTERICIDE, ANIMAL FEED SUPPLEMENT | PFIZER INC. (US) | 1976-08-03 | — | — | US | disclosed |
| US-3933797-A | 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS | PFIZER INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | ACE 1330/4885REN 195/4885LMNA 3626/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ACE 704/4885REN 263/4885LMNA 2797/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ACE 704/4885REN 263/4885LMNA 2797/4885 |
| US-20020022611-A1 | Wrinkling modifiers | AZI2, ARG1, CUTA | ACE 3621/4885REN 2500/4885LMNA 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.